ZA200201358B - Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists. - Google Patents
Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists.Info
- Publication number
- ZA200201358B ZA200201358B ZA200201358A ZA200201358A ZA200201358B ZA 200201358 B ZA200201358 B ZA 200201358B ZA 200201358 A ZA200201358 A ZA 200201358A ZA 200201358 A ZA200201358 A ZA 200201358A ZA 200201358 B ZA200201358 B ZA 200201358B
- Authority
- ZA
- South Africa
- Prior art keywords
- metabotropic glutamate
- receptor antagonists
- glutamate receptor
- heteropolycyclic compounds
- group
- Prior art date
Links
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 title abstract 2
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 title abstract 2
- 239000003825 glutamate receptor antagonist Substances 0.000 title 1
- 125000004585 polycyclic heterocycle group Chemical group 0.000 title 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 2
- 208000025966 Neurological disease Diseases 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 229910002091 carbon monoxide Inorganic materials 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14946499P | 1999-08-19 | 1999-08-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200201358B true ZA200201358B (en) | 2003-07-30 |
Family
ID=22530400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200201358A ZA200201358B (en) | 1999-08-19 | 2002-02-18 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists. |
Country Status (27)
| Country | Link |
|---|---|
| EP (1) | EP1210344B1 (enExample) |
| JP (2) | JP3790472B2 (enExample) |
| KR (1) | KR100875222B1 (enExample) |
| CN (1) | CN1313465C (enExample) |
| AT (1) | ATE307129T1 (enExample) |
| AU (1) | AU780191B2 (enExample) |
| BG (1) | BG65586B1 (enExample) |
| BR (1) | BR0013427A (enExample) |
| CA (1) | CA2381975A1 (enExample) |
| CY (1) | CY1105253T1 (enExample) |
| CZ (1) | CZ2002599A3 (enExample) |
| DE (1) | DE60023318T2 (enExample) |
| DK (1) | DK1210344T3 (enExample) |
| EE (1) | EE200200079A (enExample) |
| ES (1) | ES2250177T3 (enExample) |
| HU (1) | HUP0202757A3 (enExample) |
| IL (2) | IL148157A0 (enExample) |
| IS (1) | IS6275A (enExample) |
| MX (1) | MXPA02001764A (enExample) |
| NO (1) | NO322460B1 (enExample) |
| NZ (1) | NZ517221A (enExample) |
| PL (1) | PL353825A1 (enExample) |
| RU (1) | RU2296127C9 (enExample) |
| SK (1) | SK2512002A3 (enExample) |
| UA (1) | UA75871C2 (enExample) |
| WO (1) | WO2001012627A1 (enExample) |
| ZA (1) | ZA200201358B (enExample) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6660753B2 (en) | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| CA2438991C (en) * | 2001-02-21 | 2010-08-17 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| US6916821B2 (en) | 2001-04-02 | 2005-07-12 | Brown University | Methods of treating disorders with Group I mGluR antagonists |
| WO2002078745A2 (en) * | 2001-04-02 | 2002-10-10 | Brown University Research Foundation | Use of mglur5 antagonists in the manufacture of a medicament in the treatment of autism, mental retardation, schizophrenia |
| ES2295441T3 (es) * | 2001-12-18 | 2008-04-16 | MERCK & CO., INC. | Moduladores de pirazol heteroaril sustituido de receptor 5 metabotropico de glutamato. |
| EP1458708B1 (en) * | 2001-12-18 | 2007-09-26 | Merck & Co., Inc. | Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5 |
| EP1458385A4 (en) * | 2001-12-19 | 2005-12-21 | Merck & Co Inc | METABOTROPIC GLUTAMATE RECEPTOR 5-HETEROARYL-SUBSTITUTED IMIDAZOLE MODULATORS |
| ATE486600T1 (de) * | 2002-03-12 | 2010-11-15 | Merck Sharp & Dohme | Di-aryl-substituierte tetrazol-modulatoren des metabotropen glutamat-rezeptors-5 |
| US7964609B2 (en) | 2002-06-20 | 2011-06-21 | Astrazeneca Ab | Use of mGluR5 antagonists for the treatment of gerd |
| SE0201943D0 (sv) * | 2002-06-20 | 2002-06-20 | Astrazeneca Ab | New use |
| AR040847A1 (es) | 2002-08-09 | 2005-04-20 | Astrazeneca Ab | 1,2,4-oxadiazoles como moduladores de receptores de glutamato metabotropicos, para el tratamiento de desordenes neurologicos y psiquiatricos |
| WO2004014902A2 (en) * | 2002-08-09 | 2004-02-19 | Astrazeneca Ab | Compounds having an activity at metabotropic glutamate receptors |
| TW200424183A (en) * | 2002-08-09 | 2004-11-16 | Nps Pharma Inc | New compounds |
| GB0303503D0 (en) * | 2003-02-14 | 2003-03-19 | Novartis Ag | Organic compounds |
| AU2004227833B2 (en) * | 2003-04-04 | 2009-10-01 | Merck & Co., Inc. | Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5 |
| CA2524867A1 (en) * | 2003-05-15 | 2004-12-02 | Merck & Co., Inc. | 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists |
| WO2005060961A2 (en) * | 2003-12-18 | 2005-07-07 | Astrazeneca Ab | Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd) |
| BRPI0418149A (pt) | 2003-12-24 | 2007-04-17 | Prosidion Ltd | derivados heterocìclicos como agonistas do receptor de gprc |
| AU2005214378A1 (en) * | 2004-02-18 | 2005-09-01 | Astrazeneca Ab | Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists |
| US20070185095A1 (en) * | 2004-02-18 | 2007-08-09 | Astrazeneca Ab | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists |
| US7585881B2 (en) * | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| TW200538108A (en) | 2004-02-19 | 2005-12-01 | Astrazeneca Ab | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists |
| WO2006004142A1 (ja) * | 2004-06-30 | 2006-01-12 | Banyu Pharmaceutical Co., Ltd. | ビアリール誘導体 |
| KR100621192B1 (ko) * | 2004-10-13 | 2006-09-19 | 한국화학연구원 | 무스카린 수용체 작용물질로서 작용하는1,2,3,4-테트라하이드로피리미디닐-1,2,4-옥사다이아졸유도체와 이의 제조방법 |
| JP4557685B2 (ja) | 2004-11-15 | 2010-10-06 | 独立行政法人理化学研究所 | 蛍光蛋白質 |
| CA2593439C (en) | 2005-01-14 | 2014-02-25 | F. Hoffmann-La Roche Ag | Thiazole-4-carboxamide derivatives as mglur5 antagonists |
| GB0510142D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
| EP1896011A1 (en) * | 2005-06-28 | 2008-03-12 | AstraZeneca AB | New use |
| AU2006272978B2 (en) | 2005-07-26 | 2012-06-07 | Bial - Portela & Ca, S.A. | Nitrocatechol derivatives as COMT inhibitors |
| AR058807A1 (es) | 2005-09-29 | 2008-02-27 | Astrazeneca Ab | 5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5 |
| JP5015166B2 (ja) | 2005-11-08 | 2012-08-29 | エフ．ホフマン−ラ ロシュ アーゲー | ｍＧｌｕ５受容体アンタゴニストとしてのチアゾロ［４，５−ｃ］ピリジン誘導体 |
| US7951824B2 (en) | 2006-02-17 | 2011-05-31 | Hoffman-La Roche Inc. | 4-aryl-pyridine-2-carboxyamide derivatives |
| MX2008012738A (es) * | 2006-04-03 | 2009-02-06 | Astellas Pharma Inc | Heterocompuesto. |
| EP1845097A1 (en) | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
| US20100234349A1 (en) * | 2006-09-04 | 2010-09-16 | Olsen Gunnar M | Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer |
| CL2007002593A1 (es) | 2006-09-07 | 2008-06-13 | Actelion Pharmaceuticals Ltd | Compuestos derivados de 4-heteroaril-piridina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como rechazo de organos transplantados, sindromes autoinmunes y cancer. |
| SI2069335T1 (sl) | 2006-09-08 | 2013-04-30 | Actelion Pharmaceuticals Ltd. | Derivati piridin-3-ila kot imunomodulacijska sredstva |
| EP2069318B1 (en) | 2006-09-21 | 2012-09-12 | Actelion Pharmaceuticals Ltd. | Phenyl derivatives and their use as immunomodulators |
| CN101631548B (zh) | 2007-01-31 | 2014-08-27 | 比艾尔-坡特拉有限公司 | Comt抑制剂的单次药物剂量单元和药物组合物 |
| JP2010521450A (ja) | 2007-03-16 | 2010-06-24 | アクテリオン ファーマシューティカルズ リミテッド | Ｓ１ｐ１／ｅｄｇ１受容体アゴニストとしてのアミノ−ピリジン誘導体 |
| PL2195311T3 (pl) | 2007-08-17 | 2011-08-31 | Actelion Pharmaceuticals Ltd | Pochodne pirydynowe jako modulatory receptora S1P1/EDG1 |
| JP2011502148A (ja) | 2007-10-31 | 2011-01-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 疼痛の治療用としてのｐ２ｘ３受容体アンタゴニスト |
| CN101970430B (zh) | 2007-11-01 | 2013-05-08 | 埃科特莱茵药品有限公司 | 嘧啶衍生物 |
| RS52270B (sr) * | 2007-12-20 | 2012-10-31 | Bayer Pharma Aktiengesellschaft | 4-(4-cijano-2-tioaril)-dihidropirimidinon i njegova primena |
| CN101990433B (zh) | 2008-02-07 | 2014-11-05 | 马萨诸塞眼科耳科诊所 | 提高Atoh1表达的化合物 |
| BRPI0910288A2 (pt) | 2008-03-07 | 2019-09-24 | Actelion Pharmaceuticals Ltd | composto de derivados de aminometil benzeno, composição farmacêutica que compreende esse composto e uso do mesmo. |
| AU2009226221A1 (en) | 2008-03-17 | 2009-09-24 | Bial - Portela & Ca., S.A. | Crystal forms of 5- [3- (2, 5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl) [1,2,3] oxadiazol-5-yl] -3-nit robenzene-1, 2-diol |
| US8598209B2 (en) | 2008-10-31 | 2013-12-03 | Merck Sharp & Dohme Corp. | P2X3, receptor antagonists for treatment of pain |
| DE102009041242A1 (de) | 2009-09-11 | 2011-12-15 | Bayer Schering Pharma Aktiengesellschaft | Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung |
| DE102008057344A1 (de) | 2008-11-14 | 2010-05-20 | Bayer Schering Pharma Aktiengesellschaft | Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung |
| DE102008057343A1 (de) | 2008-11-14 | 2010-05-20 | Bayer Schering Pharma Aktiengesellschaft | Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung |
| DE102009041241A1 (de) | 2009-09-11 | 2011-08-04 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Substituierte Aryl-Verbindungen und ihre Verwendung |
| DE102008057364A1 (de) | 2008-11-14 | 2010-05-20 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Aryl-Verbindungen und ihre Verwendung |
| AU2010229142A1 (en) | 2009-03-23 | 2011-10-13 | Merck Sharp & Dohme Corp. | P2X3, receptor antagonists for treatment of pain |
| US8946231B2 (en) | 2009-03-23 | 2015-02-03 | Merck Sharp & Dohme Corp. | P2X3, receptor antagonists for treatment of pain |
| ES2660892T3 (es) | 2009-03-23 | 2018-03-26 | Merck Sharp & Dohme Corp. | Antagonistas del receptor P2X3 para el tratamiento del dolor |
| KR102023255B1 (ko) | 2009-04-01 | 2019-09-19 | 바이알 - 포르텔라 앤드 씨에이 에스에이 | 니트로카테콜 유도체를 포함하는 제약 제제 및 그의 제조 방법 |
| CA2758587A1 (en) * | 2009-04-13 | 2010-10-21 | Irm Llc | Compositions and methods for modulating retinol binding to retinol binding protein 4 (rbp4) |
| KR101409131B1 (ko) | 2009-07-16 | 2014-06-17 | 액테리온 파마슈티칼 리미티드 | 피리딘-4-일 유도체 |
| US20130058915A1 (en) | 2010-03-02 | 2013-03-07 | Children's Medica Center Corporation | Methods and compositions for treatment of angelman syndrome and autism spectrum disorders |
| SG191742A1 (en) | 2011-01-19 | 2013-08-30 | Actelion Pharmaceuticals Ltd | 2-methoxy-pyridin-4-yl derivatives |
| US20140045900A1 (en) | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
| BR112014014341A2 (pt) | 2011-12-13 | 2017-08-22 | Bial Portela & Ca Sa | Intermediário metilado, seu método de preparação e seus usos, e composição farmacêutica |
| JP5946288B2 (ja) * | 2012-02-24 | 2016-07-06 | 公立大学法人名古屋市立大学 | 新規ヒドロキサム酸誘導体及びその用途 |
| UY35327A (es) | 2013-02-15 | 2014-09-30 | Monsanto Technology Llc | ?4,5-dihidro-1,2,4-oxadiazoles disustituidos en 3,5 y composiciones y métodos para controlar plagas de nematodos?. |
| EP2853532B1 (en) * | 2013-09-28 | 2020-12-09 | Instytut Farmakologii Polskiej Akademii Nauk | 1,2,4-oxadiazole derivatives as allosteric modulators of metabotropic glutamate receptors belonging to group III |
| WO2016083863A1 (en) | 2014-11-28 | 2016-06-02 | Bial - Portela & Ca, S.A. | Medicaments for slowing parkinson's disease |
| MY192358A (en) | 2015-05-20 | 2022-08-17 | Idorsia Pharmaceuticals Ltd | Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol |
| AU2016281346B2 (en) | 2015-06-23 | 2020-01-02 | Kissei Pharmaceutical Co., Ltd. | Pyrazole derivative, or pharmaceutically acceptable salt thereof |
| MX2018011765A (es) * | 2016-03-30 | 2019-05-20 | Sinntaxis AB | Moduladores alostéricos negativos del receptor 5 metabotrópico de glutamato (mglur5) para su uso en el tratamiento de daños cerebrales maduros. |
| ES2965174T3 (es) * | 2018-04-12 | 2024-04-11 | Bayer Ag | Derivados de N-(ciclopropilmetil)-5-(metilsulfonil)-n-{1-[1-(pirimidin-2-il)-1H-1,2,4-triazol-5-il]etil}heterociclilamida y compuestos similares como plaguicidas |
| KR102276327B1 (ko) * | 2019-06-25 | 2021-07-12 | 연세대학교 산학협력단 | 신규 옥사다이아졸 화합물 및 이를 포함하는 당뇨 예방 또는 치료용 조성물 |
| WO2021046183A1 (en) * | 2019-09-05 | 2021-03-11 | Trevena, Inc. | Methods of treating epilepsy using the same |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1149011B (de) * | 1960-04-05 | 1963-05-22 | Hoechst Ag | Verfahren zur Herstellung von 3, 5-disubstituierten 1, 2, 4-Oxdiazolen |
| US3647809A (en) * | 1968-04-26 | 1972-03-07 | Chinoin Gyogyszer Es Vegyeszet | Certain pyridyl-1 2 4-oxadiazole derivatives |
| US4003909A (en) * | 1974-07-22 | 1977-01-18 | E. R. Squibb & Sons, Inc. | [(1,2,4-Oxadiazol-3-yl)phenyl]carbamic or thiocarbamic acid esters |
| US4022901A (en) * | 1975-03-05 | 1977-05-10 | E. R. Squibb & Sons, Inc. | 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles |
| AU675484B2 (en) * | 1993-03-24 | 1997-02-06 | Neurosearch A/S | Benzimidazole compounds, their use and preparation |
| US5554630A (en) * | 1993-03-24 | 1996-09-10 | Neurosearch A/S | Benzimidazole compounds |
| WO1994022846A1 (en) * | 1993-03-30 | 1994-10-13 | Pfizer Inc. | Compounds enhancing antitumor activity of other cytotoxic agents |
| RU2135493C1 (ru) * | 1995-04-21 | 1999-08-27 | Нюросерч А/С | Производное бензимидазола, фармацевтический состав и способ модуляции гамка-рецепторного комплекса |
| WO1997003967A1 (en) * | 1995-07-22 | 1997-02-06 | Rhone-Poulenc Rorer Limited | Substituted aromatic compounds and their pharmaceutical use |
| DE19643037A1 (de) * | 1996-10-18 | 1998-04-23 | Boehringer Ingelheim Kg | Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel |
| WO1999026927A2 (en) * | 1997-11-21 | 1999-06-03 | Nps Pharmaceuticals, Inc. | Metabotropic glutamate receptor antagonists for treating central nervous system diseases |
-
2000
- 2000-08-18 CN CNB008145024A patent/CN1313465C/zh not_active Expired - Fee Related
- 2000-08-18 JP JP2001517525A patent/JP3790472B2/ja not_active Expired - Fee Related
- 2000-08-18 KR KR1020027002120A patent/KR100875222B1/ko not_active Expired - Fee Related
- 2000-08-18 EP EP00955657A patent/EP1210344B1/en not_active Expired - Lifetime
- 2000-08-18 IL IL14815700A patent/IL148157A0/xx active IP Right Grant
- 2000-08-18 DE DE60023318T patent/DE60023318T2/de not_active Expired - Lifetime
- 2000-08-18 HU HU0202757A patent/HUP0202757A3/hu unknown
- 2000-08-18 SK SK251-2002A patent/SK2512002A3/sk unknown
- 2000-08-18 NZ NZ517221A patent/NZ517221A/en not_active IP Right Cessation
- 2000-08-18 AU AU67824/00A patent/AU780191B2/en not_active Ceased
- 2000-08-18 CA CA002381975A patent/CA2381975A1/en not_active Abandoned
- 2000-08-18 AT AT00955657T patent/ATE307129T1/de active
- 2000-08-18 DK DK00955657T patent/DK1210344T3/da active
- 2000-08-18 CZ CZ2002599A patent/CZ2002599A3/cs unknown
- 2000-08-18 BR BR0013427-9A patent/BR0013427A/pt not_active Application Discontinuation
- 2000-08-18 PL PL00353825A patent/PL353825A1/xx not_active Application Discontinuation
- 2000-08-18 MX MXPA02001764A patent/MXPA02001764A/es active IP Right Grant
- 2000-08-18 UA UA2002032079A patent/UA75871C2/uk unknown
- 2000-08-18 EE EEP200200079A patent/EE200200079A/xx unknown
- 2000-08-18 RU RU2002107201/04A patent/RU2296127C9/ru not_active IP Right Cessation
- 2000-08-18 ES ES00955657T patent/ES2250177T3/es not_active Expired - Lifetime
- 2000-08-18 WO PCT/US2000/022618 patent/WO2001012627A1/en not_active Ceased
-
2002
- 2002-02-14 IL IL148157A patent/IL148157A/en not_active IP Right Cessation
- 2002-02-18 IS IS6275A patent/IS6275A/is unknown
- 2002-02-18 ZA ZA200201358A patent/ZA200201358B/xx unknown
- 2002-02-19 NO NO20020823A patent/NO322460B1/no not_active IP Right Cessation
- 2002-03-07 BG BG106493A patent/BG65586B1/bg unknown
-
2005
- 2005-12-09 CY CY20051101521T patent/CY1105253T1/el unknown
-
2006
- 2006-01-25 JP JP2006016914A patent/JP2006143746A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL148157A0 (en) | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | |
| LU92113I2 (fr) | Perampanel et ses dérivés pharmaceutiquement acceptables (FYCOMPA) | |
| DE69706407D1 (de) | META-SUBSTITUIERTE PHENYLENDERIVATE UND IHRE VERWENDUNG ALS ALPHAvBETA3 INTERGRIN-ANTAGONISTEN ODER INHIBITOREN | |
| TR200102489T2 (tr) | 3-Fenilpiridin Türevleri ve bunların NK-1 alıcı antagonistler olarak kullanılması | |
| TR200201684T2 (tr) | Fenilpiperazinil türevleri | |
| DE69838662D1 (de) | Morphinanderivate und ihre medizinische Anwendung | |
| MY127120A (en) | A1 adenosine receptor antagonists | |
| GB9502644D0 (en) | Heterocyclic derivatives | |
| IL125982A0 (en) | 2-(arylphenyl) amino-imidazoline derivatives | |
| EP1016660A4 (en) | CONNECTIONS WITH [2.2.1] BICYCLIC MOLECULE STRUCTURE | |
| DE60016786D1 (de) | Bicyclische vasopressin-agoniste | |
| WO2002014275A3 (en) | Heterocyclic sulfonamide derivatives and their use for potentiating glutamate receptor function | |
| CA2364906A1 (en) | 4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy)-2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists | |
| CA2388470A1 (en) | Use of carbonylamino derivatives against cns disorders | |
| ATE234098T1 (de) | 4-aminopyrrole (3,2-d) pyrimidinen als antagonisten des neuropeptide y receptors | |
| EP1582519A3 (en) | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | |
| EP1172106A3 (en) | Use of fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles as substance P receptor antagonists | |
| ES2127699A1 (es) | Nuevos derivados de 2,3-benzodiazepina. | |
| YU38498A (sh) | Derivati 2-(arilfenil)amino-imidazolina |